Department of Pharmacology, College of Pharmacy, Harbin Medical University, Harbin, China.
State Key Laboratory of Digestive Disease, Institute of Digestive Disease and the Department of Medicine and Therapeutics, Li Ka Shing Institute of Health Sciences, CUHK Shenzhen Research Institute, The Chinese University of Hong Kong, Hong Kong SAR, China.
Cell Mol Gastroenterol Hepatol. 2024;18(6):101406. doi: 10.1016/j.jcmgh.2024.101406. Epub 2024 Sep 19.
BACKGROUND & AIMS: Sphingosine kinase 1 (SphK1) has distinct roles in the activation of Kupffer cells and hepatic stellate cells in liver fibrosis. Here, we aim to investigate the roles of SphK1 on hepatic macrophage recruitment and polarization in liver fibrosis.
Liver fibrosis was induced by carbon tetrachloride in wild-type and SphK1 mice to study the recruitment and polarization of macrophages. The effects of SphK1 originated from macrophages or other liver cell types on liver fibrosis were further strengthened by bone marrow transplantation. The direct effects of SphK1 on macrophage polarization were also investigated in vitro. Expression analysis of SphK1 and macrophage polarization index was conducted with human liver samples.
SphK1 deletion attenuated the recruitment of hepatic macrophages along with reduced M1 and M2 polarization in mice induced by carbon tetrachloride. SphK1 deficiency in endogenous liver cells attenuated macrophage recruitment via C-C motif chemokine ligand 2. Macrophage SphK1 activated the ASK1-JNK1/2-p38 signaling pathway to promote M1 polarization. Furthermore, macrophage SphK1 downregulated small ubiquitin-like modifier-specific peptidase1 to decrease de-SUMOylation of Kruppel-like factor 4 to promote M2 polarization. Finally, we confirmed that SphK1 expression was elevated and positively correlated with macrophage M1 and M2 polarization in human fibrosis livers.
Our findings demonstrated that SphK1 aggravated liver fibrosis by promoting macrophage recruitment and M1/M2 polarization. SphK1 in macrophages is a potential therapeutic target for the treatment of liver fibrosis.
鞘氨醇激酶 1(SphK1)在肝纤维化中库普弗细胞和肝星状细胞的激活中具有独特的作用。在此,我们旨在研究 SphK1 在肝纤维化中对肝巨噬细胞募集和极化的作用。
用四氯化碳诱导野生型和 SphK1 小鼠的肝纤维化,以研究巨噬细胞的募集和极化。通过骨髓移植进一步加强了来自巨噬细胞或其他肝细胞类型的 SphK1 对肝纤维化的影响。还在体外研究了 SphK1 对巨噬细胞极化的直接影响。用人肝样本进行 SphK1 表达分析和巨噬细胞极化指数。
SphK1 缺失减弱了四氯化碳诱导的小鼠肝巨噬细胞的募集,并减少了 M1 和 M2 极化。内源性肝细胞中的 SphK1 缺失通过 C-C 基序趋化因子配体 2 减弱了巨噬细胞的募集。巨噬细胞 SphK1 激活 ASK1-JNK1/2-p38 信号通路,促进 M1 极化。此外,巨噬细胞 SphK1 下调小泛素样修饰特异性肽酶 1 以减少 Kruppel 样因子 4 的去 SUMO 化,从而促进 M2 极化。最后,我们证实 SphK1 的表达在人类纤维化肝脏中升高,并与巨噬细胞 M1 和 M2 极化呈正相关。
我们的研究结果表明,SphK1 通过促进巨噬细胞募集和 M1/M2 极化加重肝纤维化。巨噬细胞中的 SphK1 是治疗肝纤维化的潜在治疗靶点。